Current Position
President and CEO of IAVI
Background
Mark Feinberg, MD, PhD, is president and CEO of IAVI where he leads a global team working to advance the development of vaccines and other biomedical innovations to protect against infection with HIV, tuberculosis, emerging viruses (including Lassa, Sudan and Marburg viruses) and other public health threats that disproportionately impact people living in low-income countries.
Experience
Prior to joining IAVI in 2015, Mark served as chief public health and science officer with Merck Vaccines. In this role, he helped advance the development and global availability of vaccines against rotavirus, human papillomavirus, and other infectious diseases. He also led a range of research initiatives to address unmet health needs in low-income countries including the coordination of a private-public partnership to expedite the development of an efficacious Ebola Zaire vaccine. Following the 2014-2016 Ebola outbreak in West Africa, Mark also played a central role in the establishment of the Coalition for Epidemic Preparedness Innovations (CEPI) and was the inaugural Chair of the CEPI Scientific Advisory Board. Previously, Mark spent more than 20 years exploring HIV/AIDS pathogenesis, treatment, and prevention research and the biology of emerging diseases in both academia and government.
Achievements
Mark is a Fellow of the American College of Medicine, and a member of the Council on Foreign Relations and the Association of American Physicians. He also serves as a member of the WHO mRNA Technology Transfer Programme Scientific and Technical Review Committee and the Vaccine Integrity Project Steering Committee.
Education
Mark holds an MD and a PhD from Stanford University, and BA degree from the University of Pennsylvania. He pursued post-graduate medical training in internal medicine at the Brigham and Women's Hospital and postdoctoral fellowship training in the laboratory of Dr. David Baltimore at the Whitehead Institute.
Previous Roles
He has previously served as a faculty member at the University of California, San Francisco and the Emory University School of Medicine, as a medical officer in the Office of AIDS Research at the National Institutes of Health (NIH) and as a fellow in the Advanced Leadership Initiative at Harvard University.
